Literature DB >> 23187140

Treatment of Tourette syndrome with cannabinoids.

Kirsten R Müller-Vahl1.   

Abstract

Cannabinoids have been used for hundred of years for medical purposes. To day, the cannabinoid delta-9-tetrahydrocannabinol (THC) and the cannabis extract nabiximols are approved for the treatment of nausea, anorexia and spasticity, respectively. In Tourette syndrome (TS) several anecdotal reports provided evidence that marijuana might be effective not only in the suppression of tics, but also in the treatment of associated behavioural problems. At the present time there are only two controlled trials available investigating the effect of THC in the treatment of TS. Using both self and examiner rating scales, in both studies a significant tic reduction could be observed after treatment with THC compared to placebo, without causing significant adverse effects. Available data about the effect of THC on obsessive-compulsive symptoms are inconsistent. According to a recent Cochrane review on the efficacy of cannabinoids in TS, definite conclusions cannot be drawn, because longer trials including a larger number of patients are missing. Notwithstanding this appraisal, by many experts THC is recommended for the treatment of TS in adult patients, when first line treatments failed to improve the tics. In treatment resistant adult patients, therefore, treatment with THC should be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23187140      PMCID: PMC5215298          DOI: 10.3233/BEN-120276

Source DB:  PubMed          Journal:  Behav Neurol        ISSN: 0953-4180            Impact factor:   3.342


  20 in total

Review 1.  Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

Authors:  Barbara S Koppel
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  [Huntington's disease].

Authors:  J D Rollnik
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

3.  The Potential of Cannabinoid-Based Treatments in Tourette Syndrome.

Authors:  Bekir B Artukoglu; Michael H Bloch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 4.  Cannabinoids and dystonia: an issue yet to be defined.

Authors:  Marcello Mario Mascia; Daniele Carmagnini; Giovanni Defazio
Journal:  Neurol Sci       Date:  2019-12-17       Impact factor: 3.307

Review 5.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

6.  Cannabinoids for the Treatment of Movement Disorders.

Authors:  Briony Catlow; Juan Sanchez-Ramos
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

7.  Interaction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strains.

Authors:  Chiara Ceci; Martina Proietti Onori; Simone Macrì; Giovanni Laviola
Journal:  Neurotox Res       Date:  2014-12-17       Impact factor: 3.911

Review 8.  Tourette Syndrome: Update.

Authors:  Mark Hallett
Journal:  Brain Dev       Date:  2015-01-17       Impact factor: 1.961

Review 9.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 10.  Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors:  Luigia Cristino; Tiziana Bisogno; Vincenzo Di Marzo
Journal:  Nat Rev Neurol       Date:  2019-12-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.